In a study examining the use of magic mushrooms in Canada, nearly 80% of participants expressed their conviction that psilocybin should be made medically available for patients in distress. Moreover, about two-thirds of the Canadian participants from the study concurred that psilocybin should be legalized for those who need it.
Besides advocating for easier access to the substance, a remarkable 84.8 percent of participants hold the view that the public health system should bear the costs of such treatments. A significant portion of Canadians view psilocybin as a promising alternative, particularly for managing end-of-life distress.
[toc]
Principal Findings:
- Inhabitants of Québec, Ontario, Alberta, and British Columbia perceive psilocybin as a legitimate medical option for addressing end-of-life existential distress.
- Magic mushrooms are deemed safe for treating existential distress.
- Participants in two double-blind trials reported immediate and long-lasting advantages, with impacts persisting six months or more.
Deciphering Existential Distress
Existential distress, similar to existential suffering, spiritual distress, and demoralization, arises when individuals confront their own mortality. Patients may experience a sense of helplessness, isolation, anxiety, and a loss of purpose and meaning. This form of distress is particularly prevalent among patients with life-threatening diseases, potentially leading to thoughts of hastening death or contemplating suicide.
Typically, individuals grappling with terminal illnesses or significant life changes are the ones who most frequently experience this form of distress. It profoundly affects their mental health and overall quality of life.
Existential therapy aims to resolve issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. It often necessitates multiple sessions and may not be effective for everyone.
The uncertainty associated with the effectiveness of such therapy is a key reason why many individuals seek alternative treatments.
The Perspective of Health Canada on Psilocybin as a Therapeutic Choice
Over the last two decades, initial clinical studies have highlighted the potential advantages of psychedelic substances in treating complex mental disorders. Specifically, Psilocybin has demonstrated quick and sustained relief from existential distress in patients facing end-of-life circumstances.
Recognizing the potential effectiveness of these proposed psychedelic mushrooms, especially when conventional treatments are inadequate, Health Canada revised the Special Access Program in 2022. This revision permits healthcare professionals to apply for controlled substances on behalf of their patients.
Canadian Advocacy for Psilocybin Access
A research article published in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Contributions from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia, 19% of whom have previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% regard psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% think psilocybin should be integrated into medical treatment. 84.8% endorse the delivery of this therapy by the public health system. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
The findings align with surveys conducted in Canada, England, and Australia. The researchers underlined the uniqueness of their study, focusing on the use of psychoactive substances to alleviate existential distress in end-of-life situations.
Justifications for Canadian Endorsement of Psilocybin Use
An increasing number of Canadians are supporting the application of psilocybin for therapy, primarily due to revelations from esteemed research institutions. Another influential factor is the perceived safety of psilocybin mushrooms in mitigating existential distress. Subjects across various studies have not reported severe adverse health effects, such as multi-organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Rapid and prolonged The effectiveness of the therapy is largely due to mystical experiences that often involve profound emotional insights and a sense of unity. These benefits can last up to six months or even longer. |
| Trial at New York University | 29 patients were randomly selected to receive either psilocybin or the active placebo niacin. | The results of the trial were in line with those of the Johns Hopkins study. Participants who received psilocybin reported significant psychological relief along with an improved outlook on life and death. |
| BMC Palliative Care | The study involved interviews with 19 participants, including 7 doctors, 4 practicing nurses, 4 chaplains, 3 social workers, and a psychologist. The aim was to understand how professionals in palliative care perceive existential distress and their views on psychedelic therapy as a potential treatment option. | According to the interviewed professionals in palliative care, psychedelic-assisted therapy (PAT) appears promising in reducing existential distress. |
Patient Experiences
In addition to scientific studies, multiple patient accounts also support the effectiveness of psilocybin in enhancing mental wellbeing and the overall quality of life.
The Journey of Yokoi
Mio Yokoi, a terminal stage 4 pancreatic cancer patient, describes a transformative experience during her assisted therapy. She visualizes herself on a raft, surrounded by nature and whimsical creatures. This vision fosters in her a profound sense of the universe’s interconnectivity and support, leading to immense peace and validation.
Despite availing traditional mental health services, Yokoi still suffered from severe anxiety and distress following her diagnosis. Psilocybin therapy allowed her to reconnect with her body and provided a tangible feeling of love and support, significantly improving her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer, which had metastasized to her lungs. At the time of the study, she was employed full-time as an administrative supervisor in healthcare and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant reductions in her anxiety, depression, fear of death, hopelessness, and demoralization levels. When asked if her religious or spiritual beliefs had changed since her therapy session, she responded affirmatively, noting that the experiences had brought depth and authenticity to her beliefs.
Brenda’s Encounter
Brenda, a lady in her sixties, received a diagnosis of stage I colon cancer. She was screened and found to have never used hallucinogens, and she also met the requirements for Chronic Adjustment Disorder with associated Anxiety.
Throughout her therapy, Brenda experienced a sensation of dying twice. She emerged from these sessions with no fear of death, seeing it as a beautiful aspect of life’s journey. She credits the study as the catalyst for her healing process from past trauma. Her results reflect this significant transformation.
Anxiety reduction, decrease in death-related fear, and increased spirituality were observed.
Availability of Magic Mushroom Products in Canada
At present, there might be limitations on the availability of psilocybin capsules and other products aimed at managing existential distress or mental health disorders. Reliable online dispensaries, however, can be a great source for these products when needed.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some surrounding South American countries. | Discovered in Cambodia, near the Angkor Wat Temple. | Associated with Penis Envy mushrooms, which became popular in the 1970s. |
| Strength | Moderately potent; appropriate for beginners. | Similarly moderate in potency; perfect for those starting out. | Highly potent; suggested for those with more extensive experience. |
| Effects | Creates a mental buzz, mild disorientation, heightened color perception, euphoria, spiritual experiences, increased creativity, and enhanced focus. | Induces a long-lasting and energizing high, minor visual changes, increased creativity, euphoria, a gentle physical high, fractal imagery, and feelings of joy. | Triggers profound shamanic experiences, vision quests, intense mystical experiences, increased creativity, focus, social consciousness, and mood upliftment. |
Ease End-of-life Discomfort with Psilocybin Products
Existential distress or end-of-life anxieties can impose a significant burden on patients nearing the end of their lives. Traditional treatments may sometimes be insufficient, prompting a rise in Canadian advocacy for broader access to magic mushrooms in public healthcare. This growing public interest could
We implore regulatory authorities to consider the potential of magic mushrooms as a beneficial treatment option. Get your psychedelics and shroom delivery from Funguyz Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
Experiences of patients undergoing Psychedelic-assisted therapy (PAT) can greatly differ. To ensure a positive outcome, it’s crucial to prepare thoroughly and follow specific procedures. Prior to substance consumption, patients should undergo a comprehensive screening and mental readiness assessment.
- Session Preparation: Patients undergo a detailed assessment. The therapist discusses the patient’s goals and expectations to set the session’s intentions. The patient is informed about the therapy’s impact and what they can expect during the session.
- The Session: A controlled dose of the substance is administered to patients in a serene, distraction-free environment to promote relaxation and self-reflection. The therapist remains available throughout to provide continuous support and guidance.
- Post-Session Integration Therapy: This therapy helps patients interpret and process their experiences. Follow-up sessions provide ongoing support and counselling to reinforce the insights and changes achieved during therapy.
What effect does psilocybin have on the brains of distressed patients?
Psilocybin interacts with the brain by binding to serotonin receptors, particularly the 5-HT2A receptor. This interaction can result in changes in perception, mood, and cognitive function, leading to profound shifts in consciousness, emotional breakthroughs, and new perspectives.
Is psilocybin therapy available to everyone?
Psilocybin therapy may not be suitable for everyone. Rigorous screening is conducted on patients with specific mental health conditions or existential distress to exclude those with a history of psychosis.
Related Articles:
